EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic Stratification of Initial Treatments for Hepatocellular Carcinoma Using a Modified Borderline Resectable Classification

Fujimasa Tada iD, Atsushi Hiraoka iD, Hideko Ohama iD, Mai Saito, Yuka Kimura iD, Ayaka Nakamura iD, Toru Usui, Kanako Kato, Kei Onishi iD, Shogo Kitahata iD, Kozue Kanemitsu-Okada iD, Tomoe Kawamura iD und 13 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.71470 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Fujimasa Tada und 24 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Although Japanese expert consensus introduced the borderline resectable (BR) criteria, additional classification is considered necessary for clinical practice. This study aimed to evaluate the prognostic predictive value of the modified BR (mBR) criteria.

Methods

From 2009 to 2024, 1056 treatment‐naïve patients with hepatocellular carcinoma (HCC) and Child‐Pugh A were enrolled (median age: 73 years). To obtain the mBR criteria, the original BR classification was modified by separately considering patients with extrahepatic metastasis (EHM, termed “boldly BR”) ( n = 42) while categorizing the rest into resectable ( n = 790), mBR1 ( n = 95), and mBR2 ( n = 129) groups. Treatments were classified as Cur (curative: surgical resection or radiofrequency ablation), NC (non‐curative: other treatment), or BSC (best supportive care). Clinical features and prognosis according to mBR criteria were analyzed retrospectively.

Results

Overall survival (OS) was stratified according to the mBR criteria (resectable/mBR1/mBR2/BBR = 113.3/49.4/30.1/10.3 months). Albumin‐bilirubin scores worsened progressively, according to the criteria (−2.70/−2.54/−2.40/−2.37), and elevated tumor marker levels (alpha‐fetoprotein [AFP] levels ≥ 100 ng/mL: 18.5%/35.8%/46.5%/59.5%; AFP‐L3 ≥ 10%: 19.8%/40.9%/54.7%/66.7%; and des‐gamma‐carboxy prothrombin levels ≥ 100 mAU/mL: 35.8%/67.4%/81.4%/90.5%, each p < 0.001) occurred more frequently in advanced groups. The Cur group in the resectable category showed significantly better OS compared with the NC and BSC groups (121.3/48.1/35.3 months, p < 0.001). Similar trends occurred in mBR1 (66.5/34.2/5.2 months) and mBR2 (57.3/22.4/7.5 months). Conversely, although some patients in the curative group had long‐term survival, treatment modality and baseline characteristics showed no prognostic impact on BBR (15.0/10.3/9.0 months).

Conclusion

Other than for patients with EHM, aggressive surgical resection may be considered a potential initial therapeutic option for advanced HCC; however, direct comparisons with other treatment modalities were not performed in this study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansAgedMaleFemalePrognosisMiddle AgedRetrospective StudiesAged, 80 and overHepatectomyAdult

Stichwörter der Autor:innen

borderline resectableextrahepatic metastasishepatocellular carcinomaresectability classification

Autor:innen und Institutionen

  • Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
  • Department of Surgery, Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
  • Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.

ORCID-Profile: Fujimasa Tada, Atsushi Hiraoka, Hideko Ohama, Yuka Kimura, Ayaka Nakamura, Kei Onishi, Shogo Kitahata, Kozue Kanemitsu-Okada, Tomoe Kawamura, Taira Kuroda, Jun Hanaoka, Jota Watanabe, Teruki Miyake, Osamu Yoshida, Masashi Hirooka, Hideki Miyata, Eiji Tsubouchi, Masanori Abe, Tomoyuki Ninomiya, Yoichi Hiasa

Zitieren

APA

Tada, F., Hiraoka, A., Ohama, H., Saito, M., Kimura, Y., Nakamura, A., Usui, T., Kato, K., Onishi, K., Kitahata, S., Kanemitsu-Okada, K., Kawamura, T., Kuroda, T., Ishimura, N., Hanaoka, J., Watanabe, J., Ohtani, H., Miyake, T., Yoshida, O., …, & Hiasa, Y. (2025). Prognostic Stratification of Initial Treatments for Hepatocellular Carcinoma Using a Modified Borderline Resectable Classification. Cancer Medicine. https://doi.org/10.1002/cam4.71470

Vancouver

Tada F, Hiraoka A, Ohama H, Saito M, Kimura Y, Nakamura A, et al. Prognostic Stratification of Initial Treatments for Hepatocellular Carcinoma Using a Modified Borderline Resectable Classification. Cancer Medicine. 2025. doi:10.1002/cam4.71470

BibTeX
@article{Tada2025,
  author = {Tada, Fujimasa and Hiraoka, Atsushi and Ohama, Hideko and Saito, Mai and Kimura, Yuka and Nakamura, Ayaka and Usui, Toru and Kato, Kanako and Onishi, Kei and Kitahata, Shogo and Kanemitsu-Okada, Kozue and Kawamura, Tomoe and Kuroda, Taira and Ishimura, Naho and Hanaoka, Jun and Watanabe, Jota and Ohtani, Hiromi and Miyake, Teruki and Yoshida, Osamu and Hirooka, Masashi and Miyata, Hideki and Tsubouchi, Eiji and Abe, Masanori and Ninomiya, Tomoyuki and Hiasa, Yoichi},
  title = {Prognostic Stratification of Initial Treatments for Hepatocellular Carcinoma Using a Modified Borderline Resectable Classification},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71470}
}
Kostenlos starten →